Safety fears spur FDA to pause checkpoint combo studies by Bristol-Myers, Celgene
Two months after the FDA ordered Merck to slam the brakes on three Keytruda combo studies targeting multiple myeloma, alarmed regulators have followed up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
